Pliant Therapeutics (STU:9PT) Inventories, Finished Goods: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9PT Pliant Therapeutics Inc STU:9PT
35 GF Score
Price €0.93
GF Value €0.38
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Pliant Therapeutics Inventories, Finished Goods?

Pliant Therapeutics STU:9PT +0.60% 35 Inventories, Finished Goods is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:9PT with a GF Score™ of 35/100 and a GF Value™ of €0.38 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Pliant Therapeutics Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Pliant Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pliant Therapeutics Inventories, Finished Goods Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pliant Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:9PT
35GF Score
Pliant Therapeutics Inc STU:9PT
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pliant Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €0.00 Mil mean?
Pliant Therapeutics (STU:9PT) has a Inventories, Finished Goods of €0.00 Mil as of Jun. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Pliant Therapeutics and its competitors.
Is Pliant Therapeutics' Inventories, Finished Goods too high?
Pliant Therapeutics' current Inventories, Finished Goods is €0.00 Mil. Overall, Pliant Therapeutics has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pliant Therapeutics' Inventories, Finished Goods compare to OSTX and GOSS?
Pliant Therapeutics' Inventories, Finished Goods of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Pliant Therapeutics and its competitors. Pliant Therapeutics's current Inventories, Finished Goods is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pliant Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Pliant Therapeutics (STU:9PT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.38, compared to a current price of €0.93 — trading 144.1% above its estimated fair value. The current Inventories, Finished Goods is €0.00 Mil. Pliant Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Pliant Therapeutics (STU:9PT), the current Inventories, Finished Goods is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pliant Therapeutics (STU:9PT) Overvalued in 2026?

Based on GuruFocus' analysis, Pliant Therapeutics stock appears to be overvalued. The current stock price of €0.93 is trading 144.1% above its estimated GF Value™ of €0.38. GuruFocus considers Pliant Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:9PT:

  • Inventories, Finished Goods: €0.00 Mil
  • GF Value™: €0.38 vs. price of €0.93 (144.1% above fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the STU:9PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pliant Therapeutics Business Description

Other Exchanges PLRX:USA
Address 331 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
35GF Score

Get the complete analysis for STU:9PT

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.93
Price
€0.38
GF Value